 |
28 Diseases |  |
0 Trials |
|
0 Trials |  |
44 News |  |
- | PI-103 / Roche, sonolisib (PX 866) / Seagen
Preclinical, Journal: Suppression of Autophagy Can Augment PIK3 Inhibitor Induced Apoptosis in T Lymphoblastic Leukemia Cell Lines. (Pubmed Central) - Aug 30, 2023
The results demonstrated that 3-MA could suppress PI3K inhibitor-mediated activation of autophagy to promote the apoptosis of tumor cells. This discovery provided experimental support for constituting a promising strategy for T-cell acute lymphoblastic leukemia (T-ALL) therapy.
- || Retrospective data, Review, Journal: Comparison of Second-Line Treatments for Patients with Platinum-Resistant Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis. (Pubmed Central) - Sep 25, 2022
Afatinib presented a better PFS and ORR than the SOC. Compared with afatinib, the PD-1 inhibitor had a better OS but a worse PFS.
- | temozolomide / Generic mfg.
Journal: Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics. (Pubmed Central) - Sep 3, 2022
Here, we tested Bcl-2 targeting drugs including ABT-737, ABT-263 (navitoclax), several natural substances such as artesunate, fisetin and curcumin as well as lomustine (CCNU) and ionizing radiation (IR) for their senolytic capacity in GBM cells...To identify senolytics, we treated the senescent population with the compounds of interest and found that ABT-737, navitoclax, chloroquine, ATMi, ATRi, BV-6, PX-866 and the natural compounds fisetin and artesunate exhibit senolytic activity, inducing death in senescent cells more efficiently than in proliferating cells...We conclude that these factors neither play a critical role in maintaining TMZ-induced CSEN nor can their inhibitors be considered as senolytics. Since IR and CCNU did not exhibit senolytic activity, radio- and chemotherapy with alkylating drugs is not designed to eliminate TMZ-induced senescent cancer cells.
- | sirolimus / Generic mfg.
Journal: Longevity Effects of DMSO-Solubilized Rapamycin and Other Compounds in y w Male Drosophila melanogaster. (Pubmed Central) - May 14, 2022
Experiments are in progress to test the effects of high dose rapamycin in male and female flies of several strains, comparing ethanol and DMSO solvents, different food recipes, lighting and storage conditions. A current conclusion is that rapamycin is not universally beneficial in Drosophila and that inhibitors of various kinases at the doses studied have limited or no effect on longevity.
- | sonolisib (PX 866) / Seagen
Journal: β-Arrestin-2 attenuates hepatic ischemia-reperfusion injury by activating PI3K/Akt signaling. (Pubmed Central) - Sep 5, 2021
Furthermore, the liver-protecting effect of ARRB2 was shown to depend on PI3K/Akt pathway activation. In summary, our results suggest that β-Arrestin-2 protects against hepatic IRI by activating PI3K/Akt signaling, which may provide a novel therapeutic strategy for treating liver ischemia-reperfusion injury.
- | sonolisib (PX 866) / Seagen
Journal, IO biomarker: The extract of Gnaphalium affine D. Don protects against HO-induced apoptosis by targeting PI3K/AKT/GSK-3β signaling pathway in cardiomyocytes. (Pubmed Central) - Mar 6, 2021
In summary, our results suggest that β-Arrestin-2 protects against hepatic IRI by activating PI3K/Akt signaling, which may provide a novel therapeutic strategy for treating liver ischemia-reperfusion injury. Our data suggested that GAE showed strong anti-oxidant effect to ameliorate oxidative stress and attenuate apoptosis induced by HO in H9c2 cells by targeting PI3K/AKT/GSK-3β signaling pathway.
- | temozolomide / Generic mfg., sonolisib (PX 866) / Seattle Genetics
Journal: Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells. (Pubmed Central) - Jul 7, 2020
The understanding of how TMZ induces survival pathways, such as autophagy, may offer new therapeutic vulnerabilities and opportunities to use sequential inhibition of alternate pro-survival pathways that regulate autophagy. As such, identification of additional ways to inhibit TMZ-induced autophagy could enhance the efficacy of TMZ.
- | sonolisib (PX 866) / Seattle Genetics
Journal: Using human Pompe disease-induced pluripotent stem cell-derived neural cells to identify compounds with therapeutic potential. (Pubmed Central) - Jun 4, 2020
Using the Pom-iPSC-derived neurons as an in vitro drug-testing model, we then identified three compounds, ebselen, wortmannin and PX-866, with therapeutic potential to alleviate Pompe disease-associated pathological phenotypes in the neurons derived from Pom-iPSCs...Moreover, they were able to enhance the GAA activity in several important internal organs of GAA-deficient mice when co-injected with recombinant human GAA, and we found that intraperitoneal injection of ebselen was able to promote the GAA activity of the GAA-heterozygous mouse brain. Our results prove the usefulness of Pom-iPSC-derived neuronal populations for identifying new compounds with therapeutic potential.
- || sonolisib (PX 866) / Seattle Genetics
Clinical, P2 data, Journal: A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. (Pubmed Central) - Mar 29, 2020
Adding AA to PX-866 showed no evidence of resistance reversal. Strategies to combine PI3K inhibition with androgen receptor-targeted therapies could consider initiation earlier, combination with other agents, and/or recruiting a selected population.
- sonolisib (PX 866) / Seattle Genetics
Next Generation Sequencing Assay Demonstrated Frequent Mutation in PI3K3CA, PI3R1 and p53 Gene in Clinically Aggressive Head Neck Squamous Cell Carcinoma (LACC West Exhibit Hall A, Poster Board Number: 89) - Jan 24, 2020 - Abstract #USCAP2020USCAP_2097;
However, this antitumor effect of PI3K inhibitors varies from one HNSCC cell line to another. The reason may be due to variations of the mutation site.
- | PI-103 / Roche, sonolisib (PX 866) / Seattle Genetics
Journal: Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells. (Pubmed Central) - Jan 2, 2020
The reason may be due to variations of the mutation site. PI3K inhibitors such as PI-103, PI-828 and PX-866 may be developed as potential therapeutic agents for effective treatment of oral squamous cell carcinoma (OSCC) patients, associated with activated PI3K/Akt pathway.
- | Journal: Mesenchymal stem cells are attracted to latent HIV-1-infected cells and enable virus reactivation via a non-canonical PI3K-NFκB signaling pathway. (Pubmed Central) - Nov 19, 2019
Furthermore, coexposure to MSC-CM enhanced the latency-reactivation efficacy of the approved LRAs, vorinostat and panobinostat. Our findings on MSC-mediated latency-reactivation may provide novel strategies against persistent HIV-1 reservoirs.
- | sonolisib (PX 866) / Seattle Genetics
Journal: Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon Nanotubes. (Pubmed Central) - Aug 17, 2019
The therapeutic efficacy of each formulation was further demonstrated by the dose-dependent cytotoxicity of SWCNT-bound PX-866 and >90% knockdown of CCR5 expression with SWCNT/siRNA transfection. This study verifies the feasibility of utilizing chirality-sorted SWCNTs for the delivery and component-specific imaging of combination therapies, also suggesting a novel nanotherapeutic approach for addressing the progressions of NASH to hepatocellular carcinoma.
- | sonolisib (PX 866) / Seagen, Zelboraf (vemurafenib) / Roche
Biomarker, Clinical, P1 data, Journal: A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600 mutant solid tumors. (Pubmed Central) - Jun 15, 2019
PX-866 was well tolerated at its maximal tolerated single-agent dose when given in combination with a modified dose of vemurafenib (720mg twice daily). Response to treatment appeared to be associated with PTEN loss and treatment with PX-866 seemed to increase CD8 T-cell infiltration in some patients.
- | sonolisib (PX 866) / Seattle Genetics
Journal: Colorectal cancer lung metastasis treatment with polymer-drug nanoparticles. (Pubmed Central) - May 5, 2019
PNPs entrapping PI3K inhibitors (i.e., wortmannin and PX866) suppressed CRC lung metastasis growth, and SN-38-loaded PNPs completely eliminated CRC lung metastasis. Our results demonstrate that polymer-drug nanoparticles offer a new approach to reduce toxicity of cancer therapy and has the potential to improve outcomes for patients with lung metastasis.
- sonolisib (PX 866) / Pfizer
Enrollment change, Metastases: Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=24, Terminated, Sponsor: Oncothyreon Inc.
Our results demonstrate that polymer-drug nanoparticles offer a new approach to reduce toxicity of cancer therapy and has the potential to improve outcomes for patients with lung metastasis. N=146 --> 24
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, sonolisib (PX 866) / Seagen
Biomarker, Journal: A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. (Pubmed Central) - Oct 18, 2017
The addition of PX-866 to cetuximab did not improve PFS, objective response rate, or OS in patients with metastatic CRC. The combination arm had greater toxicity and may have been harmful in this study.
- |||| sonolisib (PX 866) / Pfizer
Trial completion, Metastases: A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Nov 30, 2015
P2, N=68, Completed, Sponsor: NCIC Clinical Trials Group
The combination arm had greater toxicity and may have been harmful in this study. Active, not recruiting --> Completed
- |||| sonolisib (PX 866) / Pfizer
Trial completion: Phase 1 and 2 Study of PX-866 and Cetuximab (clinicaltrials.gov) - May 19, 2015
P1/2, N=178, Completed, Sponsor: Oncothyreon Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| sonolisib (PX 866) / Seagen
Trial completion: Study of PX-866 and Docetaxel in Solid Tumors (clinicaltrials.gov) - May 19, 2015
P1/2, N=223, Completed, Sponsor: Oncothyreon Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || sonolisib (PX 866) / Pfizer
Trial primary completion date, Metastases: A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Apr 25, 2015
P2, N=68, Active, not recruiting, Sponsor: NCIC Clinical Trials Group
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Jan 2015
- || sonolisib (PX 866) / Pfizer
Trial primary completion date, Metastases: A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Feb 19, 2015
P2, N=68, Active, not recruiting, Sponsor: NCIC Clinical Trials Group
Trial primary completion date: Dec 2015 --> Jan 2015 Trial primary completion date: Sep 2014 --> Dec 2015
- | sonolisib (PX 866) / Pfizer
Trial completion: A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression (clinicaltrials.gov) - Feb 19, 2015
P2, N=34, Completed, Sponsor: NCIC Clinical Trials Group
Trial primary completion date: Sep 2014 --> Dec 2015 Active, not recruiting --> Completed
- sonolisib (PX 866) / Pfizer
Trial primary completion date: A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression (clinicaltrials.gov) - Nov 12, 2014
P2, N=34, Active, not recruiting, Sponsor: NCIC Clinical Trials Group
Active, not recruiting --> Completed Trial primary completion date: Mar 2014 --> Dec 2014
- ||| sonolisib (PX 866) / Pfizer
Enrollment closed, Metastases: Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma (clinicaltrials.gov) - Mar 20, 2014
P1/2, N=146, Active, not recruiting, Sponsor: Oncothyreon Inc.
Trial primary completion date: Mar 2014 --> Dec 2014 Recruiting --> Active, not recruiting
- ||| sonolisib (PX 866) / Pfizer
Enrollment change, Metastases: A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jan 9, 2014
P2, N=68, Active, not recruiting, Sponsor: NCIC Clinical Trials Group
Recruiting --> Active, not recruiting N=40 --> 68
- ||| sonolisib (PX 866) / Pfizer
Enrollment closed, Metastases: A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jan 9, 2014
P2, N=68, Active, not recruiting, Sponsor: NCIC Clinical Trials Group
N=40 --> 68 Recruiting --> Active, not recruiting
- ||| sonolisib (PX 866) / Seagen
Enrollment closed: Study of PX-866 and Docetaxel in Solid Tumors (clinicaltrials.gov) - Oct 31, 2013
P1/2, N=206, Active, not recruiting, Sponsor: Oncothyreon Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| sonolisib (PX 866) / Pfizer
Enrollment closed: Phase 1 and 2 Study of PX-866 and Cetuximab (clinicaltrials.gov) - May 9, 2013
P1/2, N=178, Active, not recruiting, Sponsor: Oncothyreon Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| sonolisib (PX 866) / Pfizer
Trial initiation date, Metastases: Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma (clinicaltrials.gov) - Jan 7, 2013
P1/2, N=146, Active, not recruiting, Sponsor: Oncothyreon Inc.
Recruiting --> Active, not recruiting Initiation date: May 2012 --> Aug 2012
- | sonolisib (PX 866) / Pfizer
Enrollment closed: A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression (clinicaltrials.gov) - Sep 23, 2012
P2, N=34, Active, not recruiting, Sponsor: NCIC Clinical Trials Group
Initiation date: May 2012 --> Aug 2012 Recruiting --> Active, not recruiting
- ||||| sonolisib (PX 866) / Pfizer
New P1/2 trial, Metastases: Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma (clinicaltrials.gov) - Jun 7, 2012
P1/2, N=146, Active, not recruiting, Sponsor: Oncothyreon Inc.
- | sonolisib (PX 866) / Seagen
Trial completion: Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers (clinicaltrials.gov) - Mar 14, 2012
P1, N=39, Completed, Sponsor: Oncothyreon Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| sonolisib (PX 866) / Pfizer
Enrollment change: Phase 1 and 2 Study of PX-866 and Cetuximab (clinicaltrials.gov) - Oct 30, 2011
P1/2, N=178, Active, not recruiting, Sponsor: Oncothyreon Inc.
Recruiting --> Completed N=144 --> 178
- ||| sonolisib (PX 866) / Seagen
Enrollment change: Study of PX-866 and Docetaxel in Solid Tumors (clinicaltrials.gov) - Oct 30, 2011
P1/2, N=206, Active, not recruiting, Sponsor: Oncothyreon Inc.
N=144 --> 178 N=117 --> 206
- ||| sonolisib (PX 866) / Pfizer
Trial completion, Metastases: Phase I Trial of Oral PX-866 (clinicaltrials.gov) - Oct 27, 2011
P1, N=90, Completed, Sponsor: Oncothyreon Inc.
N=117 --> 206 Active, not recruiting --> Completed